{"id":"ambrisentan","rwe":[],"_fda":{"id":"14a85c38-61bf-4621-8e3a-34ab57a15758","set_id":"0e3e3320-27ac-404f-9f01-3d82696e768a","openfda":{"nui":["N0000175581","N0000175364"],"unii":["HW6NV07QEC"],"route":["ORAL"],"rxcui":["722116","722122"],"spl_id":["14a85c38-61bf-4621-8e3a-34ab57a15758"],"brand_name":["Ambrisentan"],"spl_set_id":["0e3e3320-27ac-404f-9f01-3d82696e768a"],"package_ndc":["70771-1363-3","70771-1363-9","70771-1363-1","70771-1363-8","70771-1363-7","70771-1364-3","70771-1364-9","70771-1364-1","70771-1364-8","70771-1364-7"],"product_ndc":["70771-1363","70771-1364"],"generic_name":["AMBRISENTAN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AMBRISENTAN"],"pharm_class_epc":["Endothelin Receptor Antagonist [EPC]"],"pharm_class_moa":["Endothelin Receptor Antagonists [MoA]"],"manufacturer_name":["Zydus Lifesciences Limited"],"application_number":["ANDA210058"],"is_original_packager":[true]},"version":"10","spl_medguide":["SPL MEDGUIDE"],"effective_time":"20241125","spl_unclassified_section":[""],"spl_product_data_elements":["Ambrisentan Ambrisentan AMBRISENTAN AMBRISENTAN CROSCARMELLOSE SODIUM LACTOSE MONOHYDRATE LECITHIN, SOYBEAN MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL, UNSPECIFIED POVIDONE TALC TITANIUM DIOXIDE FD&C RED NO. 40 ALUMINUM OXIDE POLYVINYL ALCOHOL, UNSPECIFIED PINK ROUND 1179 Ambrisentan Ambrisentan AMBRISENTAN AMBRISENTAN CROSCARMELLOSE SODIUM LACTOSE MONOHYDRATE LECITHIN, SOYBEAN MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL, UNSPECIFIED POVIDONE TALC TITANIUM DIOXIDE POLYVINYL ALCOHOL, UNSPECIFIED OFF WHITE OVAL 1180"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1363-3 Ambrisentan Tablets, 5 mg 30 Tablets Rx only NDC 70771-1364-3 Ambrisentan Tablets, 10 mg 30 Tablets Rx only labels label"]},"tags":[{"label":"Endothelin Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Endothelin-1 receptor","category":"target"},{"label":"EDNRA","category":"gene"},{"label":"EDNRB","category":"gene"},{"label":"C02KX02","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Pulmonary arterial hypertension","category":"indication"},{"label":"Gilead","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":5711.475,"date":"","count":7064,"signal":"Dyspnoea","source":"DrugCentral FAERS","actionTaken":"Reported 7,064 times (LLR=5711)"},{"llr":3596.979,"date":"","count":1932,"signal":"Fluid retention","source":"DrugCentral FAERS","actionTaken":"Reported 1,932 times (LLR=3597)"},{"llr":2628.087,"date":"","count":4290,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 4,290 times (LLR=2628)"},{"llr":2397.067,"date":"","count":4219,"signal":"Headache","source":"DrugCentral FAERS","actionTaken":"Reported 4,219 times (LLR=2397)"},{"llr":2294.975,"date":"","count":1477,"signal":"Nasal congestion","source":"DrugCentral FAERS","actionTaken":"Reported 1,477 times (LLR=2295)"},{"llr":2218.33,"date":"","count":1212,"signal":"Pain in jaw","source":"DrugCentral FAERS","actionTaken":"Reported 1,212 times (LLR=2218)"},{"llr":1906.132,"date":"","count":902,"signal":"Pulmonary arterial hypertension","source":"DrugCentral FAERS","actionTaken":"Reported 902 times (LLR=1906)"},{"llr":1819.23,"date":"","count":1550,"signal":"Oedema","source":"DrugCentral FAERS","actionTaken":"Reported 1,550 times (LLR=1819)"},{"llr":1500.722,"date":"","count":722,"signal":"Right ventricular failure","source":"DrugCentral FAERS","actionTaken":"Reported 722 times (LLR=1501)"},{"llr":1306.637,"date":"","count":1846,"signal":"Oedema peripheral","source":"DrugCentral FAERS","actionTaken":"Reported 1,846 times (LLR=1307)"},{"llr":1298.104,"date":"","count":870,"signal":"Pulmonary hypertension","source":"DrugCentral FAERS","actionTaken":"Reported 870 times (LLR=1298)"},{"llr":1289.621,"date":"","count":804,"signal":"Hypervolaemia","source":"DrugCentral FAERS","actionTaken":"Reported 804 times (LLR=1290)"},{"llr":1213.921,"date":"","count":968,"signal":"Unevaluable event","source":"DrugCentral FAERS","actionTaken":"Reported 968 times (LLR=1214)"},{"llr":1206.729,"date":"","count":1082,"signal":"Flushing","source":"DrugCentral FAERS","actionTaken":"Reported 1,082 times (LLR=1207)"},{"llr":966.811,"date":"","count":933,"signal":"Dyspnoea exertional","source":"DrugCentral FAERS","actionTaken":"Reported 933 times (LLR=967)"}],"commonSideEffects":[{"effect":"Peripheral edema","drugRate":"45%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"41%","severity":"common","organSystem":""},{"effect":"Nasal congestion","drugRate":"19%","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"18%","severity":"common","organSystem":""},{"effect":"Anemia","drugRate":"15%","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Bronchitis","drugRate":"10%","severity":"common","organSystem":""}],"contraindications":["Anemia","Body fluid retention","Breastfeeding (mother)","Chronic heart failure","Edema","Liver function tests abnormal","Oligozoospermia","Pregnancy, function","Pulmonary veno-occlusive disease"],"specialPopulations":{"Pregnancy":"Based on data from animal reproduction studies, ambrisentan may cause fetal harm when administered to pregnant woman and is contraindicated during pregnancy. There are limited data on ambrisentan use in pregnant women. In animal reproduction studies, ambrisentan was teratogenic in rats and rabbits at doses which resulted in exposures of 3.5 and 1.7 times, respectively, the human dose of 10 mg per day.","Geriatric use":"In the two placebo-controlled clinical studies of ambrisentan, 21% of patients were >=65 years old and 5% were >=75 years old. The elderly (age >=65 years) showed less improvement in walk distances with ambrisentan than younger patients did, but the results of such subgroup analyses must be interpreted cautiously. Peripheral edema was more common in the elderly than in younger patients.","Paediatric use":"Safety and effectiveness of ambrisentan tablets in pediatric patients have not been established. Juvenile Animal Data. In juvenile rats administered ambrisentan orally once daily during postnatal day to 26, 36, or 62, decrease in brain weight (-3% to -8%) with no morphologic or neurobehavioral changes occurred after breathing sounds, apnea, and hypoxia were observed, at exposures approximately 1.8 to 7.0 times human pediatric exposures at 10 mg, based on AUC.","Hepatic impairment":"Not recommended in patients with moderate or severe hepatic impairment."},"seriousAdverseEvents":[{"effect":"Hepatic injury","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Gilead Sciences","patents":[{"applNo":"N022081","source":"FDA Orange Book","status":"Active","expires":"Dec 11, 2027","useCode":"U-1754","territory":"US","drugProduct":false,"patentNumber":"9474752","drugSubstance":false},{"applNo":"N022081","source":"FDA Orange Book","status":"Active","expires":"Oct 14, 2031","useCode":"U-1965","territory":"US","drugProduct":false,"patentNumber":"9549926","drugSubstance":false},{"applNo":"N022081","source":"FDA Orange Book","status":"Active","expires":"Dec 11, 2027","useCode":"U-1754","territory":"US","drugProduct":false,"patentNumber":"8377933","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMBRISENTAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:27:46.832872+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:27:46.832764+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Ambrisentan","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:27:53.558716+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:27:52.318549+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:27:46.906339+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMBRISENTAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:27:52.518945+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:27:45.435600+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:27:45.435626+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:27:45.435631+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Endothelin receptor, ET-A/ET-B antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:27:53.558653+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1111/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:27:53.217367+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA210058","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:27:45.435634+00:00"}},"allNames":"letairis","offLabel":[],"synonyms":["LU208075","LU 208075","ambrisentan","letairis","volibris"],"timeline":[{"date":"2007-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GILEAD to Gilead"},{"date":"2007-06-15","type":"positive","source":"DrugCentral","milestone":"FDA approval (Gilead)"},{"date":"2019-04-10","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 7 manufacturers approved"},{"date":"2019-06-20","type":"positive","source":"DrugCentral","milestone":"EMA approval (Mylan Sas)"},{"date":"2021-03-23","type":"positive","source":"DrugCentral","milestone":"PMDA approval (GlaxoSmithKline K.K.)"}],"aiSummary":"Letairis (Ambrisentan) is a small molecule endothelin receptor antagonist developed by Gilead, targeting the endothelin-1 receptor to treat pulmonary arterial hypertension. It was FDA-approved in 2007 and remains a branded product, with multiple generic manufacturers available. As an endothelin receptor antagonist, Letairis works by blocking the action of endothelin-1, a potent vasoconstrictor, to reduce pulmonary artery pressure. Key safety considerations include potential liver enzyme elevations and teratogenic effects. Letairis is a commercially available product with a complex pharmacokinetic profile.","brandName":"Letairis","ecosystem":[{"indication":"Pulmonary arterial hypertension","otherDrugs":[{"name":"bosentan","slug":"bosentan","company":"Actelion Pharms Ltd"},{"name":"epoprostenol","slug":"epoprostenol","company":"Glaxosmithkline Llc"},{"name":"iloprost","slug":"iloprost","company":"Actelion Pharms Ltd"},{"name":"macitentan","slug":"macitentan","company":"Actelion Pharms Ltd"}],"globalPrevalence":1280000000}],"mechanism":{"target":"Endothelin-1 receptor","novelty":"Follow-on","targets":[{"gene":"EDNRA","source":"DrugCentral","target":"Endothelin-1 receptor","protein":"Endothelin-1 receptor"},{"gene":"EDNRB","source":"DrugCentral","target":"Endothelin B receptor","protein":"Endothelin B receptor"}],"moaClass":"Endothelin Receptor Antagonists","modality":"Small Molecule","drugClass":"Endothelin Receptor Antagonist [EPC]","explanation":"","oneSentence":"","technicalDetail":"Ambrisentan selectively binds to the endothelin receptor subtype A (ETA), inhibiting the vasoconstrictive and mitogenic effects of endothelin-1, leading to vasodilation and reduced pulmonary artery pressure."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ambrisentan","title":"Ambrisentan","extract":"Ambrisentan, sold under the brand name Letairis among others, is a drug used for the treatment of pulmonary hypertension. It is an endothelin receptor antagonist.","wiki_society_and_culture":"== Society and culture ==\n=== Brand names ===\nAmbrisentan is sold under the brand name Letairis, Volibris, and Pulmonext."},"commercial":{"launchDate":"2007","_launchSource":"DrugCentral (FDA 2007-06-15, GILEAD)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4337","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMBRISENTAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMBRISENTAN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Ambrisentan","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:40:04.360208","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:27:54.790338+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"bosentan","drugSlug":"bosentan","fdaApproval":"2001-11-20","patentExpiry":"May 15, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"macitentan","drugSlug":"macitentan","fdaApproval":"2013-10-18","patentExpiry":"Sep 11, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"riociguat","drugSlug":"riociguat","fdaApproval":"2013-10-08","patentExpiry":"Feb 18, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tadalafil","drugSlug":"tadalafil","fdaApproval":"2003-11-21","patentExpiry":"Dec 24, 2038","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"ambrisentan","indications":{"approved":[{"name":"Pulmonary arterial hypertension","source":"DrugCentral","snomedId":11399002,"regulator":"FDA","usPrevalence":119900000,"globalPrevalence":1280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"currentOwner":"Gilead","drugCategory":"mature","labelChanges":[],"relatedDrugs":[{"drugId":"bosentan","brandName":"bosentan","genericName":"bosentan","approvalYear":"2001","relationship":"same-class"},{"drugId":"macitentan","brandName":"macitentan","genericName":"macitentan","approvalYear":"2013","relationship":"same-class"},{"drugId":"riociguat","brandName":"riociguat","genericName":"riociguat","approvalYear":"2013","relationship":"same-class"},{"drugId":"tadalafil","brandName":"tadalafil","genericName":"tadalafil","approvalYear":"2003","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04273945","phase":"PHASE3","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-06-30","conditions":["Pulmonary Arterial Hypertension"],"enrollment":935,"completionDate":"2029-02-20"},{"nctId":"NCT07245680","phase":"PHASE3","title":"COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-15","conditions":["Pulmonary Arterial Hypertension (PAH)","Comorbidities","Cardiovascular Disease (CVD)"],"enrollment":186,"completionDate":"2029-02-14"},{"nctId":"NCT07013149","phase":"","title":"The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-08-20","conditions":["Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension (PAH)","Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)"],"enrollment":121,"completionDate":"2026-12-01"},{"nctId":"NCT07030894","phase":"PHASE4","title":"Nefecon and Ambrisentan in IgA Nephropathy","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2025-09-01","conditions":["IgA Nephropathy","Chronic Kidney Disease","Proteinuria"],"enrollment":129,"completionDate":"2026-12-31"},{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":["Pulmonary Arterial Hypertension (PAH)","Pulmonary Hypertension (PH)"],"enrollment":14000,"completionDate":"2026-12-31"},{"nctId":"NCT05039086","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-09-01","conditions":["Pulmonary Arterial Hypertension"],"enrollment":13021,"completionDate":"2022-10-04"},{"nctId":"NCT06968962","phase":"NA","title":"Comparison of Sequential to Initial Combination Therapy in PAH","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-05-14","conditions":["Pulmonary Arterial Hypertension (PAH)"],"enrollment":376,"completionDate":"2028-12"},{"nctId":"NCT06987097","phase":"NA","title":"Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-05-15","conditions":["Pulmonary Arterial Hypertension (PAH)"],"enrollment":410,"completionDate":"2029-03-01"},{"nctId":"NCT06256432","phase":"PHASE2","title":"Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome","status":"RECRUITING","sponsor":"Noorik Biopharmaceuticals AG","startDate":"2024-04-17","conditions":["Hepatorenal Syndrome","Liver Cirrhosis","Acute Kidney Injury","Ascites Hepatic"],"enrollment":54,"completionDate":"2026-02"},{"nctId":"NCT06317805","phase":"PHASE4","title":"Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients","status":"RECRUITING","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2023-12-06","conditions":["Pulmonary Arterial Hypertension"],"enrollment":110,"completionDate":"2027-06-30"},{"nctId":"NCT04393246","phase":"PHASE2,PHASE3","title":"mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2020-07-03","conditions":["COVID-19"],"enrollment":454,"completionDate":"2022-06-08"},{"nctId":"NCT04771000","phase":"PHASE2","title":"A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19","status":"TERMINATED","sponsor":"Noorik Biopharmaceuticals AG","startDate":"2021-02-08","conditions":["Covid19","Hypoxemia"],"enrollment":88,"completionDate":"2023-02-27"},{"nctId":"NCT01342952","phase":"PHASE2","title":"Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-21","conditions":["Hypertension, Pulmonary"],"enrollment":38,"completionDate":"2022-06-09"},{"nctId":"NCT04972656","phase":"NA","title":"Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-09-05","conditions":["Pulmonary Arterial Hypertension"],"enrollment":420,"completionDate":"2026-03-30"},{"nctId":"NCT05437224","phase":"PHASE3","title":"Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2018-12-18","conditions":["Pulmonary Arterial Hypertension"],"enrollment":80,"completionDate":"2022-02-06"},{"nctId":"NCT02565030","phase":"","title":"Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-02","conditions":["Chronic Thromboembolic Pulmonary Hypertension","Idiopathic Pulmonary Arterial Hypertension"],"enrollment":1200,"completionDate":"2021-10"},{"nctId":"NCT01338636","phase":"PHASE4","title":"An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-09","conditions":["Exercise-induced Pulmonary Arterial Hypertension"],"enrollment":30,"completionDate":"2016-05"},{"nctId":"NCT00593905","phase":"","title":"Pharmacogenomics in Pulmonary Arterial Hypertension","status":"WITHDRAWN","sponsor":"West Penn Allegheny Health System","startDate":"2005-07","conditions":["Pulmonary Arterial Hypertension","Pulmonary Hypertension","PAH WHO Group I"],"enrollment":0,"completionDate":"2012-07"},{"nctId":"NCT01824290","phase":"PHASE3","title":"A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-02-05","conditions":["Hypertension, Pulmonary"],"enrollment":35,"completionDate":"2021-03-10"},{"nctId":"NCT02936687","phase":"PHASE1","title":"Mechanisms of Cerebrovascular Control","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-01-31","conditions":["Metabolic Syndrome X"],"enrollment":59,"completionDate":"2021-09-30"},{"nctId":"NCT03827200","phase":"PHASE2","title":"A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis","status":"TERMINATED","sponsor":"Noorik Biopharmaceuticals AG","startDate":"2019-04-11","conditions":["Cirrhosis","Portal Hypertension","Ascites"],"enrollment":19,"completionDate":"2021-01-21"},{"nctId":"NCT02169752","phase":"NA","title":"Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"National Jewish Health","startDate":"2012-09","conditions":["Pre-Pulmonary Atrial Hypertension"],"enrollment":7,"completionDate":"2017-05-25"},{"nctId":"NCT01224210","phase":"PHASE3","title":"Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2010-03","conditions":["Portopulmonary Hypertension"],"enrollment":30,"completionDate":"2020-03"},{"nctId":"NCT01051960","phase":"PHASE4","title":"Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-03","conditions":["Systemic Sclerosis","Shortness of Breath","Pulmonary Hypertension"],"enrollment":12,"completionDate":"2011-01"},{"nctId":"NCT00777920","phase":"PHASE3","title":"Study of Ambrisentan in Participants With Pulmonary Hypertension","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-11-17","conditions":["Pulmonary Hypertension"],"enrollment":140,"completionDate":"2019-09-11"},{"nctId":"NCT01406327","phase":"","title":"Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-14","conditions":["Hypertension, Pulmonary"],"enrollment":900,"completionDate":"2020-02-28"},{"nctId":"NCT04528056","phase":"PHASE1,PHASE2","title":"Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-08-01","conditions":["Pulmonary Arterial Hypertension"],"enrollment":80,"completionDate":"2022-10-31"},{"nctId":"NCT04095286","phase":"PHASE1","title":"Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-09-30","conditions":["Hypertension, Pulmonary"],"enrollment":29,"completionDate":"2019-12-17"},{"nctId":"NCT04450095","phase":"PHASE2","title":"Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery","status":"UNKNOWN","sponsor":"Bnai Zion Medical Center","startDate":"2018-10-11","conditions":["Kidney Failure, Acute"],"enrollment":30,"completionDate":"2020-10-01"},{"nctId":"NCT00840463","phase":"PHASE4","title":"Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-01","conditions":["Pulmonary Hypertension","Heart Failure With Preserved Ejection Fraction"],"enrollment":4,"completionDate":"2014-01"},{"nctId":"NCT02290613","phase":"PHASE2","title":"Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2014-07-01","conditions":["Systemic Sclerosis","Pulmonary Hypertension"],"enrollment":38,"completionDate":"2017-12-31"},{"nctId":"NCT02712346","phase":"PHASE1","title":"The Role of Endothelin-1 in Sickle Cell Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2015-09","conditions":["Sickle Cell Anemia"],"enrollment":26,"completionDate":"2019-11-30"},{"nctId":"NCT03809156","phase":"PHASE4","title":"Upfront Combination Pulmonary Arterial Hypertension Therapy","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2016-04-26","conditions":["Pulmonary Hypertension"],"enrollment":20,"completionDate":"2021-01-31"},{"nctId":"NCT02484807","phase":"","title":"Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2015-05","conditions":["Pulmonary Arterial Hypertension"],"enrollment":125,"completionDate":"2016-12"},{"nctId":"NCT02253394","phase":"PHASE4","title":"The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2015-09","conditions":["Pulmonary Arterial Hypertension"],"enrollment":2,"completionDate":"2018-02"},{"nctId":"NCT01332331","phase":"PHASE2","title":"Efficacy and Safety of Ambrisentan in Children 8-18yrs","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-01-04","conditions":["Hypertension, Pulmonary"],"enrollment":41,"completionDate":"2013-11-12"},{"nctId":"NCT02080637","phase":"PHASE2","title":"Ambrisentan in Single Ventricle","status":"COMPLETED","sponsor":"Kevin Hill","startDate":"2015-07","conditions":["Hypoplastic Left Heart Syndrome","Hypoplastic Right-sided Heart Complex"],"enrollment":16,"completionDate":"2017-08-20"},{"nctId":"NCT02885012","phase":"PHASE4","title":"Crossover Study From Macitentan or Bosentan Over to Ambrisentan","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2016-06","conditions":["Pulmonary Arterial Hypertension"],"enrollment":3,"completionDate":"2017-07-07"},{"nctId":"NCT02688387","phase":"PHASE1","title":"A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-18","conditions":["Hypertension, Pulmonary"],"enrollment":112,"completionDate":"2017-08-04"},{"nctId":"NCT03309592","phase":"PHASE4","title":"Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension","status":"WITHDRAWN","sponsor":"Ochsner Health System","startDate":"2017-10-12","conditions":["Portopulmonary Hypertension","Pulmonary Hypertension","Cirrhosis, Liver"],"enrollment":0,"completionDate":"2018-11-01"},{"nctId":"NCT01093885","phase":"NA","title":"Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-02","conditions":["Systemic Sclerosis","Scleroderma"],"enrollment":15,"completionDate":"2016-07"},{"nctId":"NCT00851929","phase":"PHASE2,PHASE3","title":"Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2008-11","conditions":["Sarcoidosis","Pulmonary Hypertension"],"enrollment":16,"completionDate":"2011-11"},{"nctId":"NCT01971580","phase":"PHASE4","title":"The Effects of Ambrisentan on Exercise Capacity in Fontan Patients","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2012-08","conditions":["Single Ventricle Fontan Palliation"],"enrollment":28,"completionDate":"2015-05"},{"nctId":"NCT02999906","phase":"PHASE3","title":"Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension","status":"WITHDRAWN","sponsor":"United Therapeutics","startDate":"2017-10","conditions":["Pulmonary Arterial Hypertension"],"enrollment":0,"completionDate":"2022-06"},{"nctId":"NCT01178073","phase":"PHASE3","title":"A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-01","conditions":["Hypertension, Pulmonary"],"enrollment":610,"completionDate":"2014-07-31"},{"nctId":"NCT01042158","phase":"PHASE4","title":"A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2010-01","conditions":["Pulmonary Arterial Hypertension","Systemic Sclerosis","Scleroderma Spectrum of Diseases","Connective Tissue Disease","Pulmonary Hypertension"],"enrollment":25,"completionDate":"2014-11"},{"nctId":"NCT01894022","phase":"PHASE3","title":"A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2014-01-23","conditions":["Hypertension"],"enrollment":19,"completionDate":"2015-11-18"},{"nctId":"NCT01808313","phase":"PHASE3","title":"Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-01","conditions":["Vascular Disease"],"enrollment":134,"completionDate":"2014-08-15"},{"nctId":"NCT01311362","phase":"","title":"Influence of Cytochrome CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Ambrisentan","status":"COMPLETED","sponsor":"Gerd Mikus","startDate":"2011-03","conditions":["Drug Interactions"],"enrollment":20,"completionDate":"2012-12"},{"nctId":"NCT00725361","phase":"NA","title":"A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-06","conditions":["n Ulcer","Scleroderma, Systemic"],"enrollment":20,"completionDate":"2010-12"},{"nctId":"NCT00679224","phase":"","title":"An Observational Study For Ambrisentan","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06","conditions":["Hypertension, Pulmonary"],"enrollment":800,"completionDate":"2013-07"},{"nctId":"NCT01884675","phase":"PHASE3","title":"Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2013-09","conditions":["Hypertension"],"enrollment":33,"completionDate":"2015-03"},{"nctId":"NCT00424034","phase":"PHASE1","title":"A Study of GSK1325760A in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01","conditions":["Healthy Subjects"],"enrollment":32,"completionDate":"2007-02"},{"nctId":"NCT02958358","phase":"NA","title":"FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan","status":"WITHDRAWN","sponsor":"Robert Scott Harris, M.D.","startDate":"2014-09","conditions":["Pulmonary Arterial Hypertension"],"enrollment":0,"completionDate":"2016-09"},{"nctId":"NCT01733095","phase":"PHASE1,PHASE2","title":"Ambrisentan for Treatment of Portopulmonary Hypertension","status":"WITHDRAWN","sponsor":"Medical University of Graz","startDate":"2012-07","conditions":["Portopulmonary Hypertension"],"enrollment":0,"completionDate":"2016-06"},{"nctId":"NCT01902758","phase":"PHASE2,PHASE3","title":"Drug Combination on Exercise Performance at High Altitude","status":"COMPLETED","sponsor":"University of Montana","startDate":"2013-08","conditions":["Acute Mountain Sickness"],"enrollment":28,"completionDate":"2013-08"},{"nctId":"NCT01266265","phase":"","title":"Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2010-12","conditions":["Pulmonary Arterial Hypertension"],"enrollment":1333,"completionDate":"2014-12"},{"nctId":"NCT01467791","phase":"","title":"Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2011-11","conditions":["Sarcoidosis","Pulmonary Hypertension"],"enrollment":300,"completionDate":"2018-01"},{"nctId":"NCT01794078","phase":"PHASE1","title":"A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude","status":"COMPLETED","sponsor":"Robert J Noveck, M.D.","startDate":"2013-09","conditions":["Acute Mountain Sickness and Fatigue"],"enrollment":92,"completionDate":"2014-12"},{"nctId":"NCT01330108","phase":"PHASE4","title":"Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2011-05","conditions":["Pulmonary Arterial Hypertension"],"enrollment":32,"completionDate":"2012-06"},{"nctId":"NCT00879229","phase":"PHASE3","title":"ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2009-07","conditions":["Idiopathic Pulmonary Fibrosis","Pulmonary Hypertension"],"enrollment":40,"completionDate":"2011-02"},{"nctId":"NCT00768300","phase":"PHASE3","title":"(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2008-12","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":494,"completionDate":"2011-02"},{"nctId":"NCT01530464","phase":"PHASE1","title":"The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers","status":"COMPLETED","sponsor":"Thies Schroeder","startDate":"2012-02","conditions":["High Altitude Pulmonary Hypertension"],"enrollment":18,"completionDate":"2012-04"},{"nctId":"NCT00423592","phase":"PHASE2","title":"Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2005-05","conditions":["Pulmonary Hypertension"],"enrollment":36,"completionDate":"2009-03"},{"nctId":"NCT01352065","phase":"PHASE2,PHASE3","title":"Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration","status":"COMPLETED","sponsor":"Center for Health Sciences, Serbia","startDate":"2011-01","conditions":["Pulmonary Hypertension"],"enrollment":30,"completionDate":"2013-05"},{"nctId":"NCT01072669","phase":"NA","title":"Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet","status":"COMPLETED","sponsor":"Soumya Chatterjee","startDate":"2010-02","conditions":["Ischemia"],"enrollment":20,"completionDate":"2010-12"},{"nctId":"NCT00578786","phase":"PHASE3","title":"A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-02","conditions":["Pulmonary Arterial Hypertension"],"enrollment":383,"completionDate":"2010-03"},{"nctId":"NCT00554619","phase":"PHASE3","title":"A Study to Evaluate GSK1325760A - a Long-Term Extension Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02","conditions":["Pulmonary Arterial Hypertension","Hypertension, Pulmonary"],"enrollment":21,"completionDate":"2011-01"},{"nctId":"NCT00540436","phase":"PHASE2","title":"Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":["Hypertension, Pulmonary"],"enrollment":25,"completionDate":"2009-01"},{"nctId":"NCT00617305","phase":"PHASE4","title":"Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-04","conditions":["Pulmonary Arterial Hypertension"],"enrollment":38,"completionDate":"2011-07"},{"nctId":"NCT01617746","phase":"PHASE2","title":"Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma","status":"UNKNOWN","sponsor":"University of Glasgow","startDate":"2012-11","conditions":["Asthma"],"enrollment":18,"completionDate":"2015-12"},{"nctId":"NCT00380068","phase":"PHASE3","title":"Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-08","conditions":["Pulmonary Hypertension"],"enrollment":224,"completionDate":"2009-05"},{"nctId":"NCT00424021","phase":"PHASE2","title":"Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-04","conditions":["Pulmonary Hypertension"],"enrollment":54,"completionDate":"2009-12"},{"nctId":"NCT00091598","phase":"PHASE3","title":"ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-01","conditions":["Pulmonary Hypertension"],"enrollment":372,"completionDate":"2006-02"},{"nctId":"NCT00046319","phase":"PHASE2","title":"Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2002-09","conditions":["Pulmonary Hypertension"],"enrollment":60,"completionDate":"2003-06"},{"nctId":"NCT00423748","phase":"PHASE3","title":"Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-12","conditions":["Pulmonary Arterial Hypertension"],"enrollment":186,"completionDate":"2006-02"},{"nctId":"NCT00423202","phase":"PHASE3","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-12","conditions":["Pulmonary Arterial Hypertension"],"enrollment":186,"completionDate":"2005-10"}],"_emaApprovals":[{"date":"2019-06-20","status":"Authorised","company":"MYLAN SAS"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"AMBRISENTAN"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Ambrisentan"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"ambrisentan"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Letairis"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000179774","MMSL":"111024","NDDF":"012216","UNII":"HW6NV07QEC","VUID":"4026238","CHEBI":"CHEBI:135949","VANDF":"4026238","INN_ID":"8128","RXNORM":"358274","UMLSCUI":"C1176329","chemblId":"CHEMBL1111","ChEMBL_ID":"CHEMBL1111","KEGG_DRUG":"D07077","DRUGBANK_ID":"DB06403","PUBCHEM_CID":"6918493","SNOMEDCT_US":"427735003","IUPHAR_LIGAND_ID":"3951","MESH_SUPPLEMENTAL_RECORD_UI":"C467894"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"Gilead Sciences, Inc","brandName":"Letairis","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2007-","companyName":"Gilead","relationship":"Original Developer"},{"period":"2019","companyName":"Mylan Sas","relationship":"EMA Licensee"},{"period":"2021","companyName":"GlaxoSmithKline K.K.","relationship":"PMDA Licensee"}],"publicationCount":517,"therapeuticAreas":["Cardiovascular"],"_revenueScrapedAt":"2026-03-31 10:40:42.256258+00","atcClassification":{"source":"DrugCentral","atcCode":"C02KX02","allCodes":["C02KX02","C02KX52"]},"biosimilarFilings":[],"originalDeveloper":"Gilead","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":9,"_genericFilersChecked":true,"genericManufacturerList":["Apotex","Aurobindo Pharma","Cipla","Mylan","Ph Health","Sigmapharm Labs Llc","Sun Pharm","Watson Labs Inc","Zydus Pharms"],"status":"approved","companyName":"Gilead","companyId":"gilead-sciences","modality":"Small molecule","firstApprovalDate":"2007","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:27:54.790338+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}